COMP <GO>
HRTX vs ONCY // REVENUE GROWTH (YOY)
Heron Therapeutics Inc. (NASDAQ) VS. Oncolytics Biotech Inc. (NASDAQ) • 15-METRIC TALLY: HRTX 1
— ONCY 1
■ METRIC PARITY
LAST: $0.28 (-5.67%) • MKT CAP: $55.9M
revenue-growth
—
LAST: $0.43 (-0.54%) • MKT CAP: $56.1M
revenue-growth
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRTX VS. ONCY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HRTX | ONCY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 73.30% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -1.60% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -12.90% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | — | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 37.6 | 24.1 | +13.48 | HRTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $55.9M | $56.1M | -$187.8K | ONCY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HRTX REV | ONCY REV | HRTX GROSS % | ONCY GROSS % | HRTX FCF | ONCY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $154.9M | $0 | 73.3% | — | -$27.9M | -$20.1M |
| FY 2024 | $144.3M | $0 | 73.2% | — | -$24.2M | -$20.1M |
| FY 2023 | $0 | — | — | — | -$58.8M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRTX // BETA —
ONCY // BETA —